Incyte announced today its partnership with actress, singer, and songwriter Mandy Moore on Moments of Clarity, an educational initiative highlighting stories of people living with mild to moderate atopic dermatitis. Incyte is based near Wilmington.
Moore is an actress, singer and songwriter.
AD, the most common form of eczema, is a chronic condition characterized by skin inflammation which can manifest as persistent itch, dry and scaly patches or red lesions on the body1.
Through Moments of Clarity, Mandy encourages others with eczema to take charge of their health and talk to their dermatologists about finding an appropriate treatment.
“A few years ago, I noticed that the skin around my eyes was itchy, inflamed and peeling. After seeing a dermatologist, I was diagnosed with eczema,” said Moore. “I chose to partner with Incyte because I know how difficult it is to live with a chronic condition like eczema, and I want to empower others to find relief from their symptoms by speaking with their healthcare providers to learn more about treatment options.”
Moments of Clarity features stories of people with mild to moderate eczema who after realizing they needed relief from their symptoms, sought help from a dermatologist and are being treated with Incyte’s Opzelura (ruxolitinib) cream Opzelura is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in some patients.
“This program underscores Incyte’s commitment to people with AD, and we hope these stories encourage people living with the condition to have a conversation with their dermatologist about their treatment goals,” said Barry Flannelly, executive vice president and general manager, North America, Incyte. “We are grateful to Mandy Moore for partnering with us and lending her voice to help others know they are not alone in their journeys.”
To learn more, visit MyMomentsofClarity.com.
Incyte disclosed that Moore has not been treated with Incyte’s Opzelura and that she was compensated for her work.
Moore joins a number of actors with conditions who have been featured in pharma company advertisements and marketing efforts.
A representative for Incyte passed along the following safety information.
Opzelura is a non-steroidal, twice-daily cream that is FDA approved for the short-term and non-continuous treatment of mild to moderate eczema in certain people 12 and older. If you are considering Opzelura, or any eczema treatment, it’s important to talk to your dermatologist. They can partner with you to discuss your eczema treatment goals and can help determine if Opzelura is right for you.
Opzelura can cause serious side effects. It can lower your ability to fight infections including TB or hepatitis B or C. Serious lung infections, skin cancer, blood clots, and low blood cell counts occurred with OPZELURA. In people taking JAK inhibitors, serious infections, increased risk of death, lymphoma, other cancers, and major cardiovascular (heart) events have occurred. The most common side effect is the common cold. You can learn more about potential side effects and risks by speaking to your dermatologist and reading the Medication Guide. The Medication Guide is available at Opzelura.com and from your doctor. It is also included with Opzelura if it is prescribed for you.
